• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肝细胞癌血管生成的综述。

Review of angiogenesis in hepatocellular carcinoma.

作者信息

Muto Jun, Shirabe Ken, Sugimachi Keishi, Maehara Yoshihiko

机构信息

Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

出版信息

Hepatol Res. 2015 Jan;45(1):1-9. doi: 10.1111/hepr.12310. Epub 2014 Apr 2.

DOI:10.1111/hepr.12310
PMID:24533487
Abstract

Hepatocellular carcinoma (HCC) is a hypervascular tumor, and its vascularity is unique and greatly different from peripheral parenchyma of liver. Afferent and efferent vessels of HCC lesions come to differ as the lesion develops. The characteristic of the flow regulates the common style of metastasis. The portal tract of the HCC lesion is the first site of the intrahepatic metastasis, because cancer cells roll into the portal vein via efferent flow. On microscopic observation, HCC displays marked vascular abnormalities, arteriogenesis and capillarization. Arteriogenesis is defined as the growth of functional collateral arteries covered with smooth muscle cells from pre-existing arteries. Sinusoidal capillarization involves the transformation of fenestrated hepatic sinusoids into continuous capillaries. Several angiogenic factors have been reported, and some of them are studied as prognostic factors or target molecules of chemotherapeutic reagents. However, the mechanism of neovascularization during HCC development is still unclear. This review discusses the characteristics of angiogenesis in HCC and known angiogenic factors of HCC.

摘要

肝细胞癌(HCC)是一种血管丰富的肿瘤,其血管特征独特,与肝脏周边实质有很大差异。随着HCC病变的发展,其传入和传出血管会有所不同。血流特征决定了转移的常见方式。HCC病变的门静脉区域是肝内转移的首个部位,因为癌细胞通过传出血流进入门静脉。在显微镜观察下,HCC表现出明显的血管异常、动脉生成和毛细血管化。动脉生成是指从现有动脉生长出覆盖平滑肌细胞的功能性侧支动脉。窦状毛细血管化涉及有窗孔的肝血窦转变为连续毛细血管。已有多种血管生成因子被报道,其中一些被作为预后因素或化疗试剂的靶分子进行研究。然而,HCC发生发展过程中的新生血管形成机制仍不清楚。本文综述了HCC血管生成的特征以及已知的HCC血管生成因子。

相似文献

1
Review of angiogenesis in hepatocellular carcinoma.肝细胞癌血管生成的综述。
Hepatol Res. 2015 Jan;45(1):1-9. doi: 10.1111/hepr.12310. Epub 2014 Apr 2.
2
Afferent and efferent vessels of premalignant and overt hepatocellular carcinoma: observation by color Doppler imaging.癌前和显性肝细胞癌的输入和输出血管:彩色多普勒成像观察
Intervirology. 2004;47(3-5):144-53. doi: 10.1159/000078466.
3
Role of angiogenesis in hepatitis and hepatocellular carcinoma.血管生成在肝炎和肝细胞癌中的作用。
Hepatogastroenterology. 1999 Mar-Apr;46(26):646-50.
4
Pathologic and radiographic studies of intrahepatic metastasis in hepatocellular carcinoma; the role of efferent vessels.肝细胞癌肝内转移的病理及影像学研究;输出血管的作用。
HPB Surg. 1996;10(2):97-103; discussion 103-4. doi: 10.1155/1996/75210.
5
Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver.肝脏发育异常结节中的新生血管形成和血窦“毛细血管化”
Am J Surg Pathol. 1998 Jun;22(6):656-62. doi: 10.1097/00000478-199806000-00002.
6
Intrahepatic metastases in hepatocellular carcinoma: evidence for spread via the portal vein as an efferent vessel.肝细胞癌的肝内转移:通过门静脉作为输出血管发生转移的证据。
Am J Gastroenterol. 1996 Aug;91(8):1610-5.
7
Intrahepatic metastases in hepatocellular carcinoma: the role of the portal vein as an efferent vessel.肝细胞癌肝内转移:门静脉作为输出血管的作用。
Clin Exp Metastasis. 1996 Nov;14(6):520-9. doi: 10.1007/BF00115112.
8
Microvessel density and angiogenesis in primary hepatic malignancies: Differential expression of CD31 and VEGFR-2 in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.原发性肝脏恶性肿瘤中的微血管密度与血管生成:CD31和VEGFR-2在肝细胞癌和肝内胆管癌中的差异表达
Pathol Res Pract. 2018 Aug;214(8):1136-1141. doi: 10.1016/j.prp.2018.06.011. Epub 2018 Jun 19.
9
Phenotype changes in tumor vessels associated with the progression of hepatocellular carcinoma.与肝细胞癌进展相关的肿瘤血管表型变化。
Jpn J Clin Oncol. 1993 Apr;23(2):98-104.
10
Visualization of blood flow in hepatic vessels and hepatocellular carcinoma using B-flow sonography.使用B-flow超声成像技术观察肝血管及肝细胞癌中的血流情况。
J Clin Ultrasound. 2001 Jan;29(1):1-6. doi: 10.1002/1097-0096(200101)29:1<1::aid-jcu1>3.0.co;2-f.

引用本文的文献

1
Rifaximin Attenuates Liver Fibrosis and Hepatocarcinogenesis in a Rat MASH Model by Suppressing the Gut-Liver Axis and Epiregulin-IL-8-Associated Angiogenesis.利福昔明通过抑制肠-肝轴和埃匹瑞肽-IL-8相关血管生成减轻大鼠MASH模型中的肝纤维化和肝癌发生。
Int J Mol Sci. 2025 Jul 12;26(14):6710. doi: 10.3390/ijms26146710.
2
Aldolase A accelerates hepatocarcinogenesis by refactoring c-Jun transcription.醛缩酶A通过重塑c-Jun转录加速肝癌发生。
J Pharm Anal. 2025 Jul;15(7):101169. doi: 10.1016/j.jpha.2024.101169. Epub 2024 Dec 16.
3
Exosomes delivering miR-129-5p combined with sorafenib ameliorate hepatocellular carcinoma progression via the KCTD1/HIF-1α/VEGF pathway.
携带miR-129-5p的外泌体联合索拉非尼通过KCTD1/HIF-1α/VEGF途径改善肝细胞癌进展。
Cell Oncol (Dordr). 2025 Jun;48(3):743-760. doi: 10.1007/s13402-025-01044-x. Epub 2025 Apr 14.
4
Deciphering the multifaceted role of microRNAs in hepatocellular carcinoma: Integrating literature review and bioinformatics analysis for therapeutic insights.解读微小RNA在肝细胞癌中的多方面作用:整合文献综述与生物信息学分析以获取治疗见解
Heliyon. 2024 Oct 18;10(20):e39489. doi: 10.1016/j.heliyon.2024.e39489. eCollection 2024 Oct 30.
5
Benzimidazole-dioxoisoindoline conjugates as dual VEGFR-2 and FGFR-1 inhibitors: design, synthesis, biological investigation, molecular docking studies and ADME predictions.作为双 VEGFR-2 和 FGFR-1 抑制剂的苯并咪唑 - 二氧代异吲哚啉共轭物:设计、合成、生物学研究、分子对接研究及 ADME 预测
RSC Adv. 2024 Sep 12;14(39):28889-28903. doi: 10.1039/d4ra05462h. eCollection 2024 Sep 4.
6
Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021-Present).近年来用于癌症治疗的基于喹唑啉的蛋白激酶抑制剂的结构优化进展(2021 年至今)。
Molecules. 2024 Feb 16;29(4):875. doi: 10.3390/molecules29040875.
7
Receptor-based pharmacophore modeling, molecular docking, synthesis and biological evaluation of novel VEGFR-2, FGFR-1, and BRAF multi-kinase inhibitors.基于受体的新型VEGFR-2、FGFR-1和BRAF多激酶抑制剂的药效团建模、分子对接、合成及生物学评价
BMC Chem. 2024 Feb 23;18(1):42. doi: 10.1186/s13065-024-01135-0.
8
Hepatic epithelioid hemangioendothelioma-a single-institution experience with 51 cases.肝上皮样血管内皮瘤——单机构51例病例经验
Front Oncol. 2023 Aug 3;13:1236134. doi: 10.3389/fonc.2023.1236134. eCollection 2023.
9
Angiogenesis and Hepatocellular Carcinoma: From Molecular Mechanisms to Systemic Therapies.血管生成与肝细胞癌:从分子机制到系统治疗。
Medicina (Kaunas). 2023 Jun 9;59(6):1115. doi: 10.3390/medicina59061115.
10
Multifunctional nanoplatforms application in the transcatheter chemoembolization against hepatocellular carcinoma.多功能纳米平台在经导管化疗栓塞治疗肝细胞癌中的应用。
J Nanobiotechnology. 2023 Feb 27;21(1):68. doi: 10.1186/s12951-023-01820-7.